LLY

bullish · high conviction SHIFT track record →

LLY surges with FDA approval and strong 2025 growth

Watch: Monitor Foundayo's market penetration and quarterly sales as indicators of LLY's expanding weight-loss franchise performance.

Full analysis

Eli Lilly's 2025 revenue jumped 45% to $65.2 billion, powered by Zepbound's $13.5 billion (up 175%) and Mounjaro's nearly $23 billion sales. The newly FDA-approved GLP-1 pill, Foundayo, could expand its market beyond injectables, marking a key growth driver. LLY also outperformed the S&P 500 during the 2022 crash, reinforcing its defensive quality. Morgan Stanley maintains an overweight rating on the stock.

This robust revenue growth, product approval, and defensive market performance position LLY for continued earnings momentum amid competitive pressures and valuation headwinds.

Compare

Evidence

7 older signals
10d ago LLY 10-K filing change: Changes in acquired IPRD expenses and business acquisiti
10d ago LLY 10-K filing change: Changes in debt, cash, and liquidity figures
10d ago LLY 10-K filing change: Mention of litigation and product safety concerns with c
10d ago LLY 10-K filing change: Added details about U.S. government voluntary agreements
10d ago LLY 10-K filing change: New items added regarding business development focus on
10d ago LLY 10-K filing change: Mention of specific products selected for government-set
10d ago LLY 10-K filing change: New risks related to e-commerce increasing prevalence of
15 signals · latest 1h ago

Get alerted when LLY changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.